GLPwatch
Wegovy for Fertility ("Ozempic babies")
semaglutide · Investigational / off-label
Last updated 2026-05-28 15:46 UTCWegovy (semaglutide) is not FDA-approved for improving fertility. The provided research only mentions semaglutide and pregnancy, with no specific findings linking it to fertility outcomes.
AI summary of the sources below.
| Drug | Wegovy (semaglutide) |
|---|---|
| Condition | Fertility ("Ozempic babies") |
| Approval status | Investigational / off-label |
| Research papers | 10 |
Wegovy is not FDA-approved for fertility ("ozempic babies"); the research below reflects investigational or off-label study only.
Research on semaglutide for fertility ("ozempic babies") (10)
- Semaglutide and pregnancy.
- Semaglutide early intervention attenuated testicular dysfunction by targeting the GLP-1-PPAR-α-Kisspeptin-Steroidogenesis signaling pathway in a testicular ischemia-reperfusion rat model.
- Effect of Oral Semaglutide on the Pharmacokinetics of Levonorgestrel and Ethinylestradiol in Healthy Postmenopausal Women and Furosemide and Rosuvastatin in Healthy Subjects.
- Construction of human pluripotent stem cell-derived testicular organoids and their use as humanized testis models for evaluating the effects of semaglutide.
- Semaglutide ameliorates metabolic disorders in offspring via regulation of oocyte ROS of pre-pregnancy obesity mice.
- Unraveling the impact of semaglutide in a diabetic rat model of testicular dysfunction: Insights into spermatogenesis pathways and miRNA-148a-5p.
- Pre-pregnancy treatment of semaglutide improves high-fat-diet-induced placental and fetal hypothalamic alterations in a sex-specific manner in rats†.
- Semaglutide: A New Medical Swiss Army Knife?
- Semaglutide and human reproduction: caution at the intersection of energy balance, ovarian function, and follicular development.
- Impact of semaglutide exposure on fetal and neonatal outcomes in pregnant women: a systematic review.